These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 22310623)

  • 21. Donor-specific HLA antibody response in clonal deletion.
    Kaneku H; Idica A; Everly MJ; Terasaki PI; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Trivedi HL
    Clin Transpl; 2008; ():189-98. PubMed ID: 19708456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
    Kimball PM; King A
    Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay.
    Phelan D; Mohanakumar T; Ramachandran S; Jendrisak MD
    Hum Immunol; 2009 Aug; 70(8):584-8. PubMed ID: 19477211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
    Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
    Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
    Pavlakis M
    Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using donor-specific antibodies to monitor the need for immunosuppression.
    Hoshino J; Kaneku H; Everly MJ; Greenland S; Terasaki PI
    Transplantation; 2012 Jun; 93(11):1173-8. PubMed ID: 22592887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
    Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
    Cooper JE; Wiseman AC; Chan L
    Clin Transpl; 2009; ():455-9. PubMed ID: 20524314
    [No Abstract]   [Full Text] [Related]  

  • 33. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stem cells versus donor specific transfusions for tolerance induction in living donor renal transplantation: a single-center experience.
    Dave SD; Vanikar A; Trivedi HL; Gumber MR; Patel HV; Shah PR; Kute VB
    Transplantation; 2013 Jan; 95(1):155-60. PubMed ID: 23263505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of donor-recipient relationship on long-term outcomes of living related donor renal transplantation.
    Choi JY; Kwon OJ; Kang CM
    Transplant Proc; 2012 Jan; 44(1):257-60. PubMed ID: 22310626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib for acute humoral rejection in two repeat transplant recipients.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
    Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
    Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
    Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.